Mobile Menu

Search Results

Search results for: Pharmacogenetics

The potential role of PGx in managing experimental therapies for COVID-19

Since the outbreak of the COVID-19 pandemic, many clinical trials have been launched to help understand the virus and any […]

FDA releases list of evidence-based pharmacogenetic variants

Pharmacogenetics (PGx) is the study of how an individual’s genetic makeup affects their drug response and metabolism. An understanding of PGx could help clinicians make prescribing decisions and has the potential to be implemented in routine care worldwide. PGx has understandably been gaining traction and support, with pharmacogenomic elements being implemented into many international Genomic studies.

FoG 2020 Presentation Michael Barnes, QMUL: RNA Sequencing and Machine Learning as Molecular Scalpels

Professor of Bioinformatics, Director, the Centre for Translational Bioinformatics, William Harvey Research Institute, Queen Mary University of London Co-Investigator, Health […]

FoG 2020 Presentation Christopher Smither, CRUK: Exploiting Cell-Free DNA in Blood for Improved Treatment of Cancer

Chris has studied cancer genetics for the best part of ten years. Previously he studied the genetics and pharmacogenetics of […]

FoG 2020 Presentation Andrea Jorgensen, University of Liverpool: Best Practice for Integration of Biomarkers in Clinical Trials

Andrea Jorgensen is a Professor of Biostatistics at the University of Liverpool. She obtained an MSc with distinction in Medical […]

Interview with Dr Gemma Chandratillake, Education & Training Lead, Cambridge University Hospital

Dr Gemma Chandratillake is the Education and Training Lead for the East Midlands and East of England NHS Genomic Laboratory Hub.